• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Longitudinal Analysis of Risk Factors and Outcomes in Patients with Atrial Fibrillation: Stroke and Bleeding Events.心房颤动患者危险因素与预后的纵向分析:中风和出血事件
J Pharm Bioallied Sci. 2024 Jul;16(Suppl 3):S2598-S2600. doi: 10.4103/jpbs.jpbs_425_24. Epub 2024 Jul 1.
2
Longitudinal Analysis of Predictive Factors for Stroke and Bleeding Events in Atrial Fibrillation Patients: Insights From a Tertiary Care Center Cohort.心房颤动患者中风和出血事件预测因素的纵向分析:来自三级医疗中心队列的见解
Cureus. 2024 May 2;16(5):e59519. doi: 10.7759/cureus.59519. eCollection 2024 May.
3
Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).心房颤动抗凝治疗患者血栓栓塞和出血事件的风险因素:前瞻性、多中心观察性预防血栓栓塞事件-心房颤动欧洲登记研究(PREFER in AF)。
BMJ Open. 2019 Mar 30;9(3):e022478. doi: 10.1136/bmjopen-2018-022478.
4
Clinical service organisation for adults with atrial fibrillation.成人心房颤动临床服务组织。
Cochrane Database Syst Rev. 2024 Jul 29;7(7):CD013408. doi: 10.1002/14651858.CD013408.pub2.
5
[Anticoagulation status and adherence in patients with atrial fibrillation hospitalized for ACS and the impact on 1-year prognosis: a multicenter cohort study].[急性冠状动脉综合征住院房颤患者的抗凝状态、依从性及其对1年预后的影响:一项多中心队列研究]
Zhonghua Xin Xue Guan Bing Za Zhi. 2023 Jul 24;51(7):731-741. doi: 10.3760/cma.j.cn112148-20230314-00138.
6
Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry.心房颤动患者的自我报告身体活动与主要不良事件:欧洲观察性研究计划心房颤动试点调查(EORP-AF)总登记处的报告
Europace. 2017 Apr 1;19(4):535-543. doi: 10.1093/europace/euw150.
7
Association of Body Mass Index With Clinical Outcomes in Patients With Atrial Fibrillation: A Report From the FANTASIIA Registry.体重指数与心房颤动患者临床结局的关联:来自 FANTASIIA 注册研究的报告。
J Am Heart Assoc. 2020 Jan 7;9(1):e013789. doi: 10.1161/JAHA.119.013789. Epub 2019 Dec 24.
8
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.直接口服抗凝剂与华法林在预防慢性肾脏病房颤患者中风和全身性栓塞事件方面的比较
Cochrane Database Syst Rev. 2017 Nov 6;11(11):CD011373. doi: 10.1002/14651858.CD011373.pub2.
9
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.在 Outcomes Registry for Better Informed Treatment of Atrial Fibrillation 中,华法林控制指标与心房颤动结局的关系。
JAMA Cardiol. 2019 Aug 1;4(8):756-764. doi: 10.1001/jamacardio.2019.1960.
10
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.颅内出血史的房颤患者中,华法林与非维生素 K 拮抗剂口服抗凝剂使用与缺血性卒、大出血和其他不良事件的关联。
JAMA Netw Open. 2020 Jun 1;3(6):e206424. doi: 10.1001/jamanetworkopen.2020.6424.

本文引用的文献

1
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.2019年美国心脏协会/美国心脏病学会/心律学会对2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南的聚焦更新:美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会与胸外科医师协会合作报告
Circulation. 2019 Jul 9;140(2):e125-e151. doi: 10.1161/CIR.0000000000000665. Epub 2019 Jan 28.
2
Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.直接口服抗凝剂与华法林在非瓣膜性心房颤动中的围手术期结局。
Circulation. 2018 Oct 2;138(14):1402-1411. doi: 10.1161/CIRCULATIONAHA.117.031457.
3
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.直接口服抗凝剂与华法林在预防慢性肾脏病房颤患者中风和全身性栓塞事件方面的比较
Cochrane Database Syst Rev. 2017 Nov 6;11(11):CD011373. doi: 10.1002/14651858.CD011373.pub2.
4
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
5
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.ORBIT出血评分:一种用于评估房颤出血风险的简单床旁评分。
Eur Heart J. 2015 Dec 7;36(46):3258-64. doi: 10.1093/eurheartj/ehv476. Epub 2015 Sep 29.
6
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.新型口服抗凝剂与华法林治疗心房颤动患者的疗效和安全性比较:随机试验的荟萃分析。
Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.
7
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.在心房颤动患者中,Xa因子抑制剂与维生素K拮抗剂预防脑栓塞或全身性栓塞的比较
Cochrane Database Syst Rev. 2013 Aug 8(8):CD008980. doi: 10.1002/14651858.CD008980.pub2.
8
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.新型口服抗凝剂(达比加群、利伐沙班、阿哌沙班)与华法林治疗心房颤动患者的疗效和安全性的荟萃分析。
Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24.
9
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.采用新型基于风险因素的方法对房颤患者的卒中与血栓栓塞风险进行临床分层的研究:房颤的欧洲心脏调查。
Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.

心房颤动患者危险因素与预后的纵向分析:中风和出血事件

Longitudinal Analysis of Risk Factors and Outcomes in Patients with Atrial Fibrillation: Stroke and Bleeding Events.

作者信息

Gandhi Nayan Manish, Patel Ishan, Shukla Krutarth, Gami Nihar

机构信息

Gujarat Cancer Society Medical College Hospital and Research Center, Ahmedabad, Gujarat, India.

Smt. Nathiba Hargovandas Lakhmichand Municipal Medical College, Ahmedabad, Gujarat, India.

出版信息

J Pharm Bioallied Sci. 2024 Jul;16(Suppl 3):S2598-S2600. doi: 10.4103/jpbs.jpbs_425_24. Epub 2024 Jul 1.

DOI:10.4103/jpbs.jpbs_425_24
PMID:39346488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11426747/
Abstract

BACKGROUND

" (AF)" is a prevalent cardiac arrhythmia connected with augmented risk of stroke and bleeding events. Despite advancements in treatment strategies, managing AF remains challenging due to its multifactorial nature.

OBJECTIVE

This longitudinal research aimed to assess the risk factors and outcomes in subjects with AF over a specified period, focusing on stroke and bleeding events.

METHODS

Electronic health records of AF subjects were analyzed over a defined research period. Demographic information, comorbidities, medication history, and laboratory parameters were extracted. Stroke and bleeding events were identified, and statistical analyses were performed.

RESULTS

The research cohort comprised 800 AF subjects with a mean follow-up duration of 3 years. Significant risk factors for stroke and bleeding events included advancing age, hypertension, and anticoagulant use. The incidence of stroke and bleeding events augmented over the follow-up period, with notable differences in rates between patient subgroups.

CONCLUSION

This longitudinal analysis provides valuable insights into the risk factors and outcomes connected with AF, particularly stroke and bleeding events. The findings underscore the importance of proactive management strategies and personalized care approaches to optimize patient outcomes in AF.

摘要

背景

“房颤(AF)”是一种常见的心律失常,与中风和出血事件风险增加相关。尽管治疗策略有所进展,但由于房颤的多因素性质,其管理仍然具有挑战性。

目的

这项纵向研究旨在评估特定时间段内房颤患者的风险因素和结局,重点关注中风和出血事件。

方法

在规定的研究期间分析房颤患者的电子健康记录。提取人口统计学信息、合并症、用药史和实验室参数。确定中风和出血事件,并进行统计分析。

结果

研究队列包括800名房颤患者,平均随访时间为3年。中风和出血事件的重要风险因素包括年龄增长、高血压和抗凝药物使用。随访期间中风和出血事件的发生率增加,患者亚组之间的发生率存在显著差异。

结论

这项纵向分析为与房颤相关的风险因素和结局,特别是中风和出血事件,提供了有价值的见解。研究结果强调了积极管理策略和个性化护理方法对优化房颤患者结局的重要性。